Long-Term Stabilization and Storage of Peptide-Based Coacervate through Tyrosine-Rich Sequences and Polyphenol Network
Source abstract
Abstract
Peptide-based coacervates are biocompatible and tunable but inherently unstable due to weak, reversible noncovalent interactions, making them vulnerable to stress from pH and temperature. This is especially difficult for coacervates used in commercial products with low-temperature storage or lyophilization. We engineered lyophilization-tolerant nanocoacervates by incorporating aromatic tyrosine residues into oligopeptide [(YR) 2 R 10 + (YR) 2 D 10 ] and reinforcing them with tannic acid (TA). This approach leverages π–π stacking, cation−π interactions, hydrogen bonds, and electrostatic interactions to create a stabilized network. The coacervates maintain their structure, count (10 7 particles/mL), size (<500 nm), and morphology after exposure to ionic strength of 10–100 mM, pH 3–10, elevated temperatures of 25–80 °C, biological media, and, crucially, freeze drying/rehydration. The study confirms that all interactions are essential for recovery from lyophilization. This is the first peptide-based coacervate system with lyophilization tolerance, supporting scalable applications in drug delivery, biostabilization, and regenerative medicine without cold-chain storage.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Supramolecular Self-Assembly in Materials · Polymer Surface Interaction Studies · Protein Hydrolysis and Bioactive Peptides
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Aiiso Yufeng Li Family Department of Chemical and Nano Engineering
University of California, San Diego
Materials Science and Engineering Program
Department of Chemical Engineering
Massachusetts Institute of Technology
Department of Chemistry
Georgia State University
Funding
National Institutes of Health
References (53)
Show source-provided references
1. 10.1038/s44222-023-00133-610.1038/s44222-023-00133-6 ↗
2. 10.1021/acs.iecr.3c0383010.1021/acs.iecr.3c03830 ↗
3. 10.1039/D0CS00307G10.1039/D0CS00307G ↗
4. 10.1021/acsami.5c0477510.1021/acsami.5c04775 ↗
5. 10.1021/acs.accounts.3c0068910.1021/acs.accounts.3c00689 ↗
6. 10.1021/acsnano.3c0425910.1021/acsnano.3c04259 ↗
7. 10.1038/s41467-024-54463-z10.1038/s41467-024-54463-z ↗
8. 10.1038/s41467-024-51218-810.1038/s41467-024-51218-8 ↗
9. 10.1038/s41467-023-44278-910.1038/s41467-023-44278-9 ↗
10. 10.1021/jacs.4c1788010.1021/jacs.4c17880 ↗
11. 10.1007/s13346-023-01477-710.1007/s13346-023-01477-7 ↗
12. 10.1021/acs.biomac.3c0004310.1021/acs.biomac.3c00043 ↗
13. 10.1021/jacs.3c0774810.1021/jacs.3c07748 ↗
14. 10.1016/j.carbpol.2025.12388010.1016/j.carbpol.2025.123880 ↗
15. 10.1016/j.jcis.2025.13782610.1016/j.jcis.2025.137826 ↗
16. 10.1021/acsami.3c0072710.1021/acsami.3c00727 ↗
17. 10.1021/jacs.4c1446910.1021/jacs.4c14469 ↗
18. 10.1038/s41467-024-53699-z10.1038/s41467-024-53699-z ↗
19. 10.1002/adma.20220291310.1002/adma.202202913 ↗
20. 10.1021/jacs.1c0114810.1021/jacs.1c01148 ↗
21. 10.1039/C4TB01213E10.1039/C4TB01213E ↗
22. 10.3390/pharmaceutics1311192410.3390/pharmaceutics13111924 ↗
23. 10.1021/la303211b10.1021/la303211b ↗
24. 10.1021/acsbiomaterials.4c0110510.1021/acsbiomaterials.4c01105 ↗
25. 10.1021/acs.biomac.8b0086310.1021/acs.biomac.8b00863 ↗
26. 10.1002/advs.20180125510.1002/advs.201801255 ↗
27. 10.1021/jp050418p10.1021/jp050418p ↗
28. 10.1021/la015697w10.1021/la015697w ↗
29. 10.1039/C6RA10889J10.1039/C6RA10889J ↗
30. 10.1007/s12010-015-1613-310.1007/s12010-015-1613-3 ↗
31. 10.1016/j.progpolymsci.2024.10190810.1016/j.progpolymsci.2024.101908 ↗
32. 10.1039/D1RA07657D10.1039/D1RA07657D ↗
33. 10.1021/acsomega.2c0167910.1021/acsomega.2c01679 ↗
34. 10.1007/s00289-020-03160-010.1007/s00289-020-03160-0 ↗
35. 10.1039/C6NJ00185H10.1039/C6NJ00185H ↗
36. 10.1021/acs.jpcb.4c0852610.1021/acs.jpcb.4c08526 ↗
37. 10.1038/s41598-018-20669-710.1038/s41598-018-20669-7 ↗
38. 10.3390/biomedicines1012327610.3390/biomedicines10123276 ↗
39. 10.1002/ange.20170416210.1002/ange.201704162 ↗
40. 10.1093/nar/gkm21010.1093/nar/gkm210 ↗
41. 10.1016/j.ijpharm.2023.12305110.1016/j.ijpharm.2023.123051 ↗
42. 10.3109/08982104.2014.99202310.3109/08982104.2014.992023 ↗
43. 10.2147/IJN.S12306210.2147/IJN.S123062 ↗
44. 10.1016/j.ijpharm.2023.12308410.1016/j.ijpharm.2023.123084 ↗
45. 10.1016/j.jconrel.2016.01.03410.1016/j.jconrel.2016.01.034 ↗
46. 10.1016/j.ejpb.2021.10.01410.1016/j.ejpb.2021.10.014 ↗
47. 10.34133/bmr.000510.34133/bmr.0005 ↗
48. 10.1016/j.isci.2022.10512710.1016/j.isci.2022.105127 ↗
49. 10.1021/acsami.5c0972610.1021/acsami.5c09726 ↗
50. 10.1039/c2fo00006g10.1039/c2fo00006g ↗
51. 10.3389/fnut.2024.137140110.3389/fnut.2024.1371401 ↗
52. 10.3390/antiox1208157710.3390/antiox12081577 ↗
53. 10.1016/j.tifs.2023.10419310.1016/j.tifs.2023.104193 ↗